Meshram Rohan J, Baladhye Vijay B, Gacche Rajesh N, Karale Bhausaheb K, Gaikar Rajendra B
Assistant Professor, The Bioinformatics Centre, Savitribai Phule Pune University, Pune, Maharashtra, India.
Professor, Department of Botany, School of Life Sciences, Swami Ramanand Teerth Marathwada University, Nanded, Maharashtra, India.
J Clin Diagn Res. 2017 May;11(5):KF01-KF08. doi: 10.7860/JCDR/2017/22761.9925. Epub 2017 May 1.
Compounds containing thiadiazole moiety are cognized to possess with variety of clinical and therapeutic activity. Finding a suitable drug target for newly synthesized compounds remain a major bottle neck in current high throughout medicinal chemistry era.
To effectively synthesize di substituted thiadiazole compounds and demonstrate drug target identification using an in silico pharmacophore probing approach. Moreover, we also aim to validate the suitability of identified drug target.
A cost-effective and environmental friendly chemical synthesis scheme for production of di substituted thiadiazole compounds was employed. Target identification was conducted by Pharmmapper software. Validation was accomplished by performing molecular docking and further Molecular Hydrophobic Potential (MHP) analysis.
Pharmacophore probing base approach identified hepatocyte growth factor receptor (c-Met) as a suitable biological target for newly synthesized compounds. Binding free energy values indicate that compound 4b, 4e, 4g and 4h has tremendous potential to be further used as lead compound to design selective inhibitors of c-Met receptor. MHP data from current study supports the possibility that hydrophobic contacts might act as major factor stabilizing thiadiazole- c-Met complex. Moreover, in silico observations of current study are in absolute accordance with previously described in vitro and crystallographic analysis.
We demonstrate that thiadiazole compounds synthesized in current investigation has high potential to act in modulation of hepatocyte growth factor receptor (c-Met) activity and thereby act as putative therapeutic agent in cancer therapy.
含有噻二唑部分的化合物被认为具有多种临床和治疗活性。在当前高通量药物化学时代,为新合成的化合物寻找合适的药物靶点仍然是一个主要瓶颈。
有效合成二取代噻二唑化合物,并使用计算机辅助药效团探测方法证明药物靶点的识别。此外,我们还旨在验证所识别药物靶点的适用性。
采用一种经济高效且环境友好的化学合成方案来生产二取代噻二唑化合物。通过Pharmmapper软件进行靶点识别。通过进行分子对接和进一步的分子疏水势(MHP)分析来完成验证。
基于药效团探测的方法将肝细胞生长因子受体(c-Met)识别为新合成化合物的合适生物靶点。结合自由能值表明化合物4b、4e、4g和4h具有巨大潜力,可进一步用作先导化合物来设计c-Met受体的选择性抑制剂。当前研究的MHP数据支持疏水相互作用可能是稳定噻二唑-c-Met复合物的主要因素这一可能性。此外,当前研究的计算机模拟观察结果与先前描述的体外和晶体学分析完全一致。
我们证明,当前研究中合成的噻二唑化合物具有很高的潜力来调节肝细胞生长因子受体(c-Met)的活性,从而在癌症治疗中作为一种推定的治疗剂发挥作用。